Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering
July 17, 2018 18:55 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 17, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly
June 21, 2018 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 21, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel...
Crinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical Officer
June 18, 2018 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 18, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel...
Crinetics Pharmaceuticals Completes $63.5 Million Series B Financing
March 13, 2018 14:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced it...
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO 2018
March 12, 2018 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 12, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced an...
Crinetics Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference
March 07, 2018 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 07, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that...
Crinetics Pharmaceuticals Appoints Marc Wilson as Chief Financial Officer
January 04, 2018 09:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the...
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 02, 2018 09:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that...
Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly
October 26, 2017 10:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the...
Crinetics Pharmaceuticals Awarded Two SBIR Grants to Develop New Therapeutics for Congenital Hyperinsulinism and Cushing’s Disease
September 06, 2017 09:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that...